Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27852989)
Watch
English
Ceritinib in ALK-rearranged non-small-cell lung cancer
scientific article
Ceritinib inALK-Rearranged Non–Small-Cell Lung Cancer
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
24670165
retrieved
13 November 2016
title
Ceritinib in ALK-rearranged non-small-cell lung cancer
(English)
1 reference
stated in
PubMed
PubMed ID
24670165
retrieved
13 November 2016
main subject
ceritinib
1 reference
based on heuristic
inferred from title
lung cancer
1 reference
based on heuristic
inferred from title
author
Armando Santoro
object named as
Armando Santoro
series ordinal
17
0 references
Enriqueta Felip
object named as
Enriqueta Felip
series ordinal
5
0 references
Geoffrey Liu
object named as
Geoffrey Liu
series ordinal
16
0 references
D Ross Camidge
series ordinal
7
object named as
D Ross Camidge
0 references
Gregory J Riely
series ordinal
11
object named as
Gregory J Riely
0 references
author name string
Alice T Shaw
series ordinal
1
0 references
Dong-Wan Kim
series ordinal
2
0 references
Ranee Mehra
series ordinal
3
0 references
Daniel S W Tan
series ordinal
4
0 references
Laura Q M Chow
series ordinal
6
0 references
Johan Vansteenkiste
series ordinal
8
0 references
Sunil Sharma
series ordinal
9
0 references
Tommaso De Pas
series ordinal
10
0 references
Benjamin J Solomon
series ordinal
12
0 references
Juergen Wolf
series ordinal
13
0 references
Michael Thomas
series ordinal
14
0 references
Martin Schuler
series ordinal
15
0 references
Yvonne Y Lau
series ordinal
18
0 references
Meredith Goldwasser
series ordinal
19
0 references
Anthony L Boral
series ordinal
20
0 references
Jeffrey A Engelman
series ordinal
21
0 references
language of work or name
English
0 references
publication date
27 March 2014
0 references
published in
The New England Journal of Medicine
0 references
volume
370
0 references
issue
13
0 references
page(s)
1189-97
0 references
cites work
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
20 March 2017
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
20 March 2017
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
20 March 2017
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
20 March 2017
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
20 March 2017
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
20 March 2017
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
20 March 2017
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
7 April 2017
ALK in lung cancer: past, present, and future
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
29 September 2017
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
29 September 2017
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
29 September 2017
Anaplastic lymphoma kinase in human cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
29 September 2017
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
29 September 2017
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
29 September 2017
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
29 September 2017
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
2 June 2018
Cancer phase I clinical trials: efficient dose escalation with overdose control.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
2 June 2018
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
27 November 2018
Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
27 November 2018
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
27 November 2018
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
27 November 2018
Critical aspects of the Bayesian approach to phase I cancer trials.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
27 November 2018
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079055
retrieved
27 November 2018
Identifiers
DOI
10.1056/NEJMOA1311107
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
8421
OpenCitations bibliographic resource ID
8421
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
8421
PMCID
4079055
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
8421
PubMed ID
24670165
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
8421
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
